Furthermore, recent data has shown that TTP patients (ADAMTS13 <10%) have A-IPCs at presentation that are markedly decreased compared to healthy controls that differentiates this group from other thrombocytopenic patients without the enzyme deficiency (24, 46, 47), and in some, such as refractory TTP cases, it may facilitate adjustments in therapy (48, 49). This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.